Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


November 24th, 2022

Patrys AGM Highlights

Novel antibody company Patrys (PAB: $0.021) held its AGM this week. The presentation by its CEO James Campbell is worth reading closely.

November 4th, 2022

Imricor Medical Systems to Focus on Dedicated MRI Labs

Imricor Medical Systems (IMR: $0.275) achieved consumable revenue of just US$115,000 for the quarter, down 15% on the previous corresponding period. However, it has increased the number of active sites by three to nine sites.

November 4th, 2022

Pharmaxis Releases Initial Data in Myelofibrosis

Pharmaxis (PXS: $0.066) has two drug candidates in clinical development, both based on its lysyl oxidase inhibition platform that seeks to reduce or stop collagen crosslinking that is crucial to the fibrosis process. The drug candidates are PXS-5505, being trialled in a Phase II study in myelofibrosis, and a second investigator-led study in liver cancer due to commence this year; as well as PXS-6302, which is being investigated as a treatment for existing and new scars. The trial in existing scars has reached the 75% recruitment mark.

November 4th, 2022

Aroa Biosurgery - Revenue Up 44%

Aroa Biosurgery (ARX: $0.86) continues to outperform. Revenue for its first half (ending 30 September) was up 44% on the PCP to NZ$29 million. Surprisingly it has also delivered a positive EBITDA for the half year, ahead of expectations. Aroa is forecasting to be EBITDA neutral for the full year.

November 4th, 2022

Cogstate Signs US$17.9 Million of Contracts in September Quarter

Cogstate (CGS: $1.77) has achieved another very strong quarter of sales contracts totalling US$17.9 million after US$1.1 million in contract cancellations. Its net cashflow was just US$0.2 million.

October 18th, 2022

Dimerix – Recruitment Accelerating in Phase III Study

Dimerix (DXB: $0.165) has reached around 40% recruitment into the first part of its Phase III focal segmental glomerulosclerosis (FSGS) study (as of mid September). The global study is seeking to recruit 286 patients for final analysis across 70 sites. The interim readout will be on 72 patients measuring proteinurea after 35 weeks of treatment.

October 18th, 2022

Antisense Therapeutics Revises Clinical Program in DMD

With a deterioration in capital markets, Antisense Therapeutics (ANP: $0.86) has adjusted its clinical program in Duchenne's Muscular Dystrophy with its lead drug candidate ATL1102. The company had previously intended to conduct a potentially pivotal Phase IIb/III study in 114 patients. That has now been changed to a Phase IIb program that will seek to enroll 45 subjects.

October 5th, 2022

Pharmaxis - Encouraging Early Data from Scar Removal Study

Pharmaxis (PXS: $0.081) has released some data on the first eight patients treated with its drug candidate, PXS-6302, to remove existing scars. The first eight patients were all treated with PXS-6302 whilst the next 42 being recruited are blinded between placebo or active arms.

October 5th, 2022

Anteris Technologies - Aortic Valve Outperforms Surgical and TAVR Competitors

Aortic heart valve company Anteris Technologies (AVR: $23.10) had multiple presentations at the major US conference TCT (Transcatheter Cardiovascular Therapeutics) held in Boston last month. The event has around 11,000 specialists in the field attending and was founded by Dr Martin Leon, who has joined the Anteris Medical Advisory Board earlier this year.

October 5th, 2022

Eisai Delivers Positive Phase III Alzheimer's Data

Cogstate's (CGS: $2.09) partner, Eisai Co Ltd, has for the first time in this disease area, delivered unequivocally positive data for its Alzheimer's disease treatment, lecanamab.

Eisai will now seek to file the therapy for full approval with the FDA by the end of March. Eisai will use Cogstate's electronic cognitive test battery to help identify potential patients for treatment, under a US$45 million deal signed in 2020 between the two companies.